Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.
The TRYP Management team has decades of experience building successful pharmaceutical and biotech companies together, and bring a balanced combination of capital markets experience, Big Pharma and FDA expertise (having successfully brought drugs to market), and a track record of building profitable public companies.
James Kuo, Chief Executive Officer
Chairman of the Board, ImmunoPrecise Antibodies (TSXV:IPA).
Former Managing Director of HealthCare Ventures, a $378 Million venture capital fund.
Former CEO of BioMicro Systems and Discovery Laboratories.
Former Associate Director of Licensing and Development at Pfizer.
MD from University of Pennsylvania School of Medicine.
MBA from the Wharton School of Business.
William Garner, Executive Chairman
Founder of Race Oncology (ASX:RAC)
Co-Founder and Director of DelMar Pharmaceuticals (NASDAQ:DMPI)
Founder of EGB Ventures, where he was focused on advancing technologies and companies to monetization or assets via licensing, mergers and acquisitions or IPO transactions.
Previous Big Pharma experience at Pfizer & QLT leading larger partnerships & product portfolios.
MBA, Vanderbilt University & BSc in Chemistry from Loyola University, Chicago
Dr. Jim Gilligan, President & Chief Science Officer
PhD from the University of Connecticut & MBA from Seton Hall University
Over 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs, and CMC manufacturing.
Co-Founder of Unigene Laboratories
Co-Founder & Chief Science Office of Tarsa Therapeutics
Pipeline / Market Opportunities
TRYP’s PFN™ Program
Tryp’s PFN™ program is focused on developing orally-delivered drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs that are currently in the market or are in development.
TRP-8802 | Fibromyalgia
Chronic and debilitating CNS/neurobiological disorder. The fibromyalgia treatment market is estimated to surpass US$3.6B by 2026.
TRP-1001 | Razoxane (Soft Tissue Sarcomas)
Oncology is the leading therapeutic category and represented 25% of all drug sales in 2018, which equated to ~US$151B in 2018.
GET THE HEADLINES + UPDATES
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.